Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.
about
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A ReviewEffects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.The effect of SGLT2 inhibitors on cardiovascular events and renal function.Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects.Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes.The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure.Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.Novel avenues for treating diabetic nephropathy: new investigational drugs.Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks.Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.Un-sweetening the Heart: Possible pleiotropic effects of SGLT2 inhibitors on cardio and cerebrovascular alterations in resistant hypertensive subjects.Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects.The effect of liraglutide on renal function: A randomized clinical trial.Baseline characteristics and enrichment results of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial.New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors.Oxidative Stress, Apoptosis, and Mitochondrial Function in Diabetic Nephropathy.Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice.Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study
P2860
Q28079134-135C161D-EFB7-4E4D-98C9-35A51E9B5D66Q32186373-230A2D33-421D-4CBD-AB44-263BBF48F409Q33696974-AA964C45-5F0C-4CF9-A9A6-D84790598A64Q37588847-1CE651E0-6FE9-4933-BD34-7024FAC231D8Q38614488-162E5EB7-9EBC-4D7D-8AFE-6E5E1D9ECCF8Q38635763-C28C679F-86C3-42AC-90B6-29D9A13BB39BQ38645792-C392631B-33C9-4070-9D92-438428E7D7A2Q38735470-D42010CF-EDAF-498A-8FAC-1681270FEDE1Q38906470-E7E28F2A-5987-4275-BE91-FBADA9C6A81DQ38932322-D36413B2-3C96-4C85-B83B-46BD46D540F4Q39013664-8252F470-46BD-4262-BD61-EE42AF9B1351Q39039079-0568AB2E-7101-4520-9346-05922242C1F3Q39170387-92D31340-132E-47B0-A222-DEF795FD2497Q39170860-A8521F80-554E-4DBF-A765-F5387B05C5A6Q39255188-83B4A842-3D33-46F3-A8A5-2B778CD1196FQ39290337-5C6792FE-0F50-48C9-9742-9A28DC7B0B3EQ42388524-2570BD56-2E24-46FC-8726-06C1C7D6A1A4Q43742584-DD24EC27-FB6E-4769-8797-31998C49CB44Q46320593-334E1D2C-C555-448F-903A-317144AAD4AAQ47134445-A1556C79-6A4A-4BD1-A2E5-DC88A45B0732Q49550551-FFC218E7-10E2-4C02-BA4E-022B6617C13DQ50027868-5EAB8E6B-15A0-4C66-817B-DA65545B93C1Q51381510-7431AFD0-92B5-4E4C-803C-3051F87E3E0CQ51731767-3E1E614F-4FD4-441E-BC72-408DDCE6234DQ51733588-F7D846C0-3739-4E57-BAAC-F860C8BC6AB4Q52889769-5446BB47-7370-42D1-9BA2-5743EA1DA456Q53599452-08B67603-8A29-464B-B514-E9E055BC203CQ54977897-1DE82EB5-CC13-4D65-A8E7-02152EB84148Q55174679-2D7B32E3-A24E-4754-A906-F6C33F38B933Q55476982-9DB7FEC8-8555-4EC3-A44E-7136513E68B9Q57136996-62BEEFB5-DA0A-4C96-8DBF-ACDB782BC0F8
P2860
Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Dapagliflozin reduces albuminu ...... ng renin-angiotensin blockers.
@en
type
label
Dapagliflozin reduces albuminu ...... ng renin-angiotensin blockers.
@en
prefLabel
Dapagliflozin reduces albuminu ...... ng renin-angiotensin blockers.
@en
P2093
P2860
P356
P1476
Dapagliflozin reduces albuminu ...... ng renin-angiotensin blockers.
@en
P2093
C D Sjöström
E Johnsson
H J L Heerspink
I Gause-Nilsson
P2860
P304
P356
10.1111/DOM.12654
P577
2016-03-03T00:00:00Z